Perman 6,489,335*
5932,283
6,376,517

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1153cxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 42	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC

```
NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
              CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
              AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS INTER    General Internet Information
NEWS LOGIN    Welcome Banner and News Items
NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 17:36:14 ON 11 FEB 2003

=> file caplus uspatful europatful japio medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 17:36:41 ON 11 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:36:41 ON 11 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EUROPATFULL' ENTERED AT 17:36:41 ON 11 FEB 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

FILE 'JAPIO' ENTERED AT 17:36:41 ON 11 FEB 2003
COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'MEDLINE' ENTERED AT 17:36:41 ON 11 FEB 2003

FILE 'BIOSIS' ENTERED AT 17:36:41 ON 11 FEB 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:36:41 ON 11 FEB 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

=> s macrolide and (dry eye)
L1          14 MACROLIDE AND (DRY EYE)

=> s l1 and FK506
L2          11 L1 AND FK506

=> d l2 1-11 ibib abs

L2   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:        2000:790310  CAPLUS
```

DOCUMENT NUMBER: 133:317582
TITLE: Use of **macrolide** compounds for the treatment of **dry eye**
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066122	A1	20001109	WO 2000-JP2756	20000426
W: AL, AU, BR, CA, CN, CZ, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, RO, RU, SI, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1173177	A1	20020123	EP 2000-921047	20000426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000011225	A	20020319	BR 2000-11225	20000426
JP 2002543132	T2	20021217	JP 2000-615007	20000426
NO 2001005288	A	20011029	NO 2001-5288	20011029

PRIORITY APPLN. INFO.: US 1999-132009P P 19990430
WO 2000-JP2756 W 20000426
OTHER SOURCE(S): MARPAT 133:317582
AB The present invention provides an agent for treating a **dry eye**, which contains a **macrolide** compd. such as **FK506**.
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 11 USPATFULL
ACCESSION NUMBER: 2003:38097 USPATFULL
TITLE: Use of a CD40:CD154 binding interruptor to treat immunological complications of the eye
INVENTOR(S): Dana, M. Reza, Belmont, MA, UNITED STATES
Vaishnaw, Akshay K., Arlington, MA, UNITED STATES
Burkly, Linda C., West Newton, MA, UNITED STATES
Lobb, Roy, Westwood, MA, UNITED STATES
Adelman, Burt, Concord, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003027744	A1	20030206
APPLICATION INFO.:	US 2002-125264	A1	20020418 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-US28945, filed on 19 Oct 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-160909P	19991022 (60)
	US 2000-196453P	20000411 (60)
	US 2000-229491P	20000831 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 1485
AB The invention relates generally to the treatment and inhibition of immunological complications of the eye. Such complications include unwanted immune responses resulting in an ocular inflammatory disease, resulting from a corneal or retinal graft transplantation or resulting from ocular angiogenesis, particularly ocular neovascularization. The invention relates in particular to the inhibition, treatment, or reversal of immune-system driven rejection of grafted corneal or retinal tissue or cells in a recipient host and to the treatment or inhibition of ocular inflammatory disease or ocular neovascularization in a host.

Compositions and methods disclosed herein capitalize on the discovery that immunological complications of the eye can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody.

L2 ANSWER 3 OF 11 USPATFULL
ACCESSION NUMBER: 2003:24201 USPATFULL
TITLE: Treatment of ocular disease
INVENTOR(S): Peyman, Gholam A., New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018044	A1	20030123
APPLICATION INFO.:	US 2002-247220	A1	20020919 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-507076, filed on 18 Feb 2000, GRANTED, Pat. No. US 6489335
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Beverly A. Lyman, Wood, Herron & Evans, L.L.P., 2700 Carew Tower, 441 Vine Street, Cincinnaty, OH, 45202-2917
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation to treat ocular disease such as **dry eye** disease, as well as other diseases, is disclosed. Tacrolimus is administered intraocularly, such as topically or by injection. For topical administration, an amount of about 1 ng to 10 .mu.g may be formulated in an aqueous based cream that may be applied at bedtime or throughout the day. For injection, a dose of about 20-1000 .mu.g/ml is used. Tacrolimus may also be administered in milligram quantities as a surgical implant contained in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 11 USPATFULL
ACCESSION NUMBER: 2002:216865 USPATFULL
TITLE: Sustained release preparations
INVENTOR(S): Yamashita, Kazunari, Muko, JAPAN
Hashimoto, Eiji, Hashimoto, JAPAN
Nomura, Yukihiro, Osaka, JAPAN
Shimojo, Fumio, Kawanishi, JAPAN

Tamura, Shigeki, Osaka, JAPAN
Hirose, Takeo, Kyoto, JAPAN
Ueda, Satoshi, Kawanishi, JAPAN
Saitoh, Takashi, Osaka, JAPAN
Ibuki, Rinta, Kyoto, JAPAN
Ideno, Toshio, Takatsuki, JAPAN

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6440458	B1	20020827	
	WO 9949863		19991007	
APPLICATION INFO.:	US 1999-403787		19991105	(9)
	WO 1999-JP1499		19990325	
			19991105	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-79039	19980326
	JP 1998-182963	19980629

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Ware, Todd D.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Providing an oral formulation of a **macrolide** compound where the dissolution of the **macrolide** compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the **macrolide** compound is present at an amorphous state in a solid base.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 11 USPATFULL
ACCESSION NUMBER: 2002:119919 USPATFULL
TITLE: Medicinal compositions
INVENTOR(S): Ibuki, Rinta, Kyoto, JAPAN
Shimojo, Fumio, Hyogo, JAPAN
Ueda, Satoshi, Hyogo, JAPAN
Toyoda, Toshihiko, Hyogo, JAPAN
Yamanaka, Masayuki, Hyogo, JAPAN
Yoshida, Erika, Hyogo, JAPAN

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, JAPAN, 541-8514 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002061907	A1	20020523	
APPLICATION INFO.:	US 2001-5645	A1	20011207	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-673260, filed on 22 Nov 2000, PENDING A 371 of International Ser. No. WO 1999-JP2237, filed on 26 Apr 1999, UNKNOWN			

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-117271	19980427

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB To provide a pharmaceutical composition comprising a **macrolide** compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 11 USPATFULL
ACCESSION NUMBER: 2002:84927 USPATFULL
TITLE: Sustained release preparations
INVENTOR(S): Yamashita, Kazunari, Kyoto, JAPAN
Hashimoto, Eiji, Wakayama, JAPAN
Nomura, Yukihiro, Osaka, JAPAN
Shimojo, Fumio, Hyogo, JAPAN
Tamura, Shigeki, Osaka, JAPAN
Hirose, Takeo, Kyoto, JAPAN
Ueda, Satoshi, Hyogo, JAPAN
Saitoh, Takashi, Osaka, JAPAN
Ibuki, Rinta, Kyoto, JAPAN
Ideno, Toshio, Osaka, JAPAN
PATENT ASSIGNEE(S): FUJISAWA PHARMACEUTICAL CO., LTD., OSAKA, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002044967	A1	20020418
APPLICATION INFO.:	US 2001-978025	A1	20011017 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-403787, filed on 5 Nov 1999, PENDING A 371 of International Ser. No. WO 1999-JP1499, filed on 25 Mar 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-79039	19980326
	JP 1998-182963	19980629

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC, FOURTH FLOOR, 1755 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 1568
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Providing an oral formulation of a **macrolide** compound where the dissolution of the **macrolide** compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the **macrolide** compound is present at an amorphous state in a solid base.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 11 USPATFULL
ACCESSION NUMBER: 2002:22504 USPATFULL
TITLE: Treatment of ocular disease
INVENTOR(S): Peyman, Gholam A., New Orleans, LA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013340	A1	20020131
	US 6489335	B2	20021203
APPLICATION INFO.:	US 2000-507076	A1	20000218 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Beverly A Lyman, Wood Herron & Evans LLP, 2700 Carew Tower, Cincinnati, OH, 45202-2917
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 283
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation to treat ocular disease such as **dry eye** disease, as well as other diseases, is disclosed. Tacrolimus is administered either topically or by injection. For topical administration, an amount of about 1 ng to 10 .mu./g may be formulated in an aqueous based cream that may be applied at bedtime or throughout the day. For injection, a dose of about 20-1000 .mu.g/ml is used. Tacrolimus may also be administered in milligram quantities as a surgical implant contained in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 11 USPATFULL
ACCESSION NUMBER: 2001:237481 USPATFULL
TITLE: Use of rapamycin and agents that inhibit B7 activity in immunomodulation
INVENTOR(S): Sypek, Joseph, Newton, MA, United States
Collins, Mark J., Candia, NH, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001055593	A1	20011227
APPLICATION INFO.:	US 2001-805800	A1	20010313 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-189106P	20000314 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2232
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides methods for downmodulating an immune response comprising contacting immune cells from a subject with at least one agent that binds to at least one B7 molecule in combination with a Rapamycin compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 11 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1159962 EUROPATFULL EW 200149 FS OS
TITLE: LIPOSOME PREPARATIONS.
LIPOSOMZUBEREITUNG.
PREPARATIONS LIPOSOMIQUES.
INVENTOR(S): FUJISAKI, Jiro, 31-1-217, Mibutsujimachi, Nakagyo-ku, Kyoto-shi, Kyoto 604-8822, JP;
KONNO, Hajime, 55-24, Tsunoecho 1-chome, Takatsuki-shi, Osaka 569-0822, JP;
KASAI, Akihiro, 1-2-606, Haginodai 5-chome, Ikoma-shi, Nara 630-0224, JP;
OHTOMO, Kazumi, 11-3, Funakicho, Ibaraki-shi, Osaka 567-0828, JP
PATENT ASSIGNEE(S): FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome Chuo-ku, Osaka-shi Osaka 541-8514, JP
PATENT ASSIGNEE NO: 204383
AGENT: Gille Hrabal Struck Neidlein Prop Roos, Patentanwaelte, Brucknerstrasse 20, 40593 Duesseldorf, DE
AGENT NUMBER: 100973
OTHER SOURCE: BEPA2001098 EP 1159962 A1 0018
SOURCE: Wila-EPZ-2001-H49-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1159962	A1	20011205
'OFFENLEGUNGS' DATE:		20011205
APPLICATION INFO.: EP 2000-907979		20000310
PRIORITY APPLN. INFO.: JP 1999-65469		19990311
JP 1999-151866		19990531
RELATED DOC. INFO.: WO 00-JP1446		000310 INTAKZ
WO 0053177		000914 INTPNR

L2 ANSWER 10 OF 11 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1074255 EUROPATFULL EW 200106 FS OS
TITLE: MEDICINAL COMPOSITIONS.
MEDIZINISCHE ZUSAMMENSTELLUNGEN.
COMPOSITIONS MEDICINALES.
INVENTOR(S): IBUKI, Rinta, 7, Koyama Higashigenicho Kita-ku, Kyoto-shi Kyoto 603-8104, JP;
SHIMOJO, Fumio, 2-2-13, Daiwahigashi, Kawanishi-shi Hyogo 666-0111, JP;
UEDA, Satoshi, 1-16-3, Shinden, Kawanishi-shi Hyogo 666-0125, JP;
TOYODA, Toshihiko, 3-5-17-807, Higashitada, Kawanishi-shi Hyogo 666-0122, JP;
YAMANAKA, Masayuki, 3-26-30-402, Minamimukonoso, Amagasaki-shi Hyogo 661-0033, JP;

	YOSHIDA, Erika, 2-24-4, Kozukayamahonmachi Tarumi-ku, Kobe-shi Hyogo 655-0003, JP
PATENT ASSIGNEE(S):	FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome Chuo-ku, Osaka-shi Osaka 541-8514, JP
PATENT ASSIGNEE NO:	204383
AGENT:	Gille Hrabal Struck Neidlein Prop Roos, Patentanwaelte, Brucknerstrasse 20, 40593 Duesseldorf, DE
AGENT NUMBER:	100973
OTHER SOURCE:	BEPA2001011 EP 1074255 A1 0016
SOURCE:	Wila-EPZ-2001-H06-T1b
DOCUMENT TYPE:	Patent
LANGUAGE:	Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES:	R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE
PATENT INFO.PUB.TYPE:	EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1074255	A1	20010207
'OFFENLEGUNGS' DATE:		20010207
APPLICATION INFO.: EP 1999-917179		19990426
PRIORITY APPLN. INFO.: JP 1998-117271		19980427
RELATED DOC. INFO.: WO 99-JP2237		990426 INTAKZ
WO 9955332		991104 INTPNR

L2 ANSWER 11 OF 11 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER:	1064942 EUROPATFULL EW 200101 FS OS
TITLE:	SUSTAINED RELEASE PREPARATIONS. ARZNEIZUBEREITUNGEN MIT VERZOeGERTER WIRKSTOFFABGABE. PREPARATIONS A LIBERATION PROLONGEE.
INVENTOR(S):	YAMASHITA, Kazunari, 13-1-403, Uemachida, Morimoto-cho, Muko-shi, Kyoto 617-0003, JP; HASHIMOTO, Eiji, 791-44, Sumidacho Kawase, Hashimoto-shi, Wakayama 648-0015, JP; NOMURA, Yukihiro, 2-6-8, Matsumushidori, Abeno-ku, Osaka-shi, Osaka 545-0043, JP; SHIMOJO, Fumio, 2-2-13, Daiwahigashi, Kawanishi-shi, Hyogo 666-0111, JP; TAMURA, Shigeki, 2-13-2-702, Houshin, Higashiyodagawa-ku, Osaka-shi, Osaka 533-0014, JP; HIROSE, Takeo, Chayamachi 525, Yamatoojidori Shomensagaru, Higashiyama-ku, Kyoto-shi, Kyoto 605-0933, JP; UEDA, Satoshi, 1-16-3, Shinden, Kawanishi-shi, Hyogo 666-0125, JP; SAITOH, Takashi, 3-9-8-906, Daito-cho, Miyakojima-ku, Osaka-shi, Osaka 534-0002, JP; IBUKI, Rinta, 7, Koyama Higashigenicho, Kita-ku, Kyogo-shi, Kyoto 603-8104, JP; IDENO, Toshio, 4-4-18, Akutagawa-cho, Takatsuki-shi, Osaka 569-1123, JP
PATENT ASSIGNEE(S):	FUJISAWA PHARMACEUTICAL CO., LTD., 4-7, Doshomachi 3-chome Chuo-ku, Osaka-shi Osaka 541-8514, JP
PATENT ASSIGNEE NO:	204383
AGENT:	Gille Hrabal Struck Neidlein Prop Roos, Patentanwaelte, Brucknerstrasse 20, 40593 Duesseldorf, DE
AGENT NUMBER:	100973

OTHER SOURCE: BEPA2001001 EP 1064942 A1 0033
SOURCE: Wila-EPZ-2001-H01-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Japanisch; Veroeffentlichung in Englisch; Verfahren in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R NL; R PT; R SE; R SI
PATENT INFO.PUB.TYPE: EPA1 EUROPAEISCHE PATENTANMELDUNG (Internationale Anmeldung)
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 1064942	A1	20010103
'OFFENLEGUNGS' DATE:			20010103
APPLICATION INFO.:	EP 1999-909332		19990325
PRIORITY APPLN. INFO.:	JP 1998-79039		19980326
	JP 1998-182963		19980629
RELATED DOC. INFO.:	WO 99-JP1499	990325	INTAKZ
	WO 9949863	991007	INTPNR

on 18 Feb 2000, GRANTED, Pat. No. US 6489335
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Beverly A. Lyman, Wood, Herron & Evans, L.L.P., 2700 Carew Tower, 441 Vine Street, Cincinnaty, OH, 45202-2917
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A formulation to treat ocular disease such as **dry eye** disease, as well as other diseases, is disclosed. Tacrolimus is administered intraocularly, such as topically or by injection. For topical administration, an amount of about 1 ng to 10 .mu.g may be formulated in an aqueous based cream that may be applied at bedtime or throughout the day. For injection, a dose of about 20-1000 .mu.g/ml is used. Tacrolimus may also be administered in milligram quantities as a surgical implant contained in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 11 USPATFULL
ACCESSION NUMBER: 2002:216865 USPATFULL
TITLE: Sustained release preparations
INVENTOR(S): Yamashita, Kazunari, Muko, JAPAN
Hashimoto, Eiji, Hashimoto, JAPAN
Nomura, Yukihiro, Osaka, JAPAN
Shimojo, Fumio, Kawanishi, JAPAN
Tamura, Shigeki, Osaka, JAPAN
Hirose, Takeo, Kyoto, JAPAN
Ueda, Satoshi, Kawanishi, JAPAN
Saitoh, Takashi, Osaka, JAPAN
Ibuki, Rinta, Kyoto, JAPAN
Ideno, Toshio, Takatsuki, JAPAN
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6440458	B1	20020827	
	WO 9949863		19991007	
APPLICATION INFO.:	US 1999-403787		19991105	(9)
	WO 1999-JP1499		19990325	
			19991105	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-79039	19980326
	JP 1998-182963	19980629

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Ware, Todd D.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1310

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Providing an oral formulation of a **macrolide** compound where the dissolution of the **macrolide** compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the **macrolide** compound is present at an amorphous state in a solid

WEST Search History

DATE: Tuesday, February 11, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L5	L4 and treat$	163	L5
L4	L3 and (local administration)	163	L4
L3	L2 and FK506	164	L3
L2	L1 and ophthalm$	468	L2
L1	macrolide and (dry eye)	2023	L1

END OF SEARCH HISTORY